GYNIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNIX (GYNIX).
Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.
| Metabolism | Not metabolized; acts locally via direct chemical action. |
| Excretion | Primarily renal (approximately 60-80% as unchanged drug) and biliary (20-30% as metabolites; unchanged drug not detected in bile). Fecal elimination accounts for <5%. |
| Half-life | Terminal half-life is 2.5-3 hours in patients with normal renal function; prolonged to 6-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 12-15 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 20-30% bound to albumin with negligible binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd is 0.8-1.1 L/kg (range 0.6-1.3 L/kg), indicating extensive tissue distribution (e.g., lung, liver, bone). |
| Bioavailability | Oral: 85-95% (immediate-release) and 70-80% (sustained-release due to first-pass effect). Vaginal: 5-10% (minimal systemic absorption). IV: 100%. |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes (rapid antibacterial effect); Topical (vaginal): within 1 hour (local effect). |
| Duration of Action | Oral: 8-12 hours (sustained release formulation provides 24-hour coverage); IV: 12 hours; Topical: 24 hours (single dose). Clinical note: Extended duration due to high tissue penetration. |
| Molecular Weight | 181.19 |
1 vaginal tablet (100 mg) once daily at bedtime for 7 days
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min: use with caution, consider alternative therapy. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe (Child-Pugh C): contraindicated. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No dose adjustment required; use same as adult dosing. |
| 1st trimester | Contraindicated due to risk of teratogenicity (malformations in animal studies; no adequate human data). |
| 2nd trimester | Contraindicated; risk of fetal nephrotoxicity and oligohydramnios. |
| 3rd trimester | Contraindicated; risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for GYNIX (GYNIX).
| Placental transfer | Crosses placenta readily; achieves therapeutic concentrations in fetal circulation. |
| Breastfeeding | Excreted in human milk in low concentrations; however, due to potential adverse effects in nursing infants (e.g., kernicterus in neonates), alternative agents preferred. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to GYNIX or any componentThird trimester of pregnancySignificant hepatic impairment
| Precautions | Avoid contact with normal tissue; risk of chemical burns; not for use on neoplastic lesions. |
| Food/Dietary | No known food interactions with topical use. However, avoid concurrent use of iodine-containing supplements or medications, as it may increase systemic iodine load. |
| Clinical Pearls | GYNIX (povidone-iodine) is a topical antiseptic. Avoid use in patients with iodine hypersensitivity or thyroid disorders (e.g., Hashimoto's thyroiditis). Prolonged use on large wounds may cause iodine absorption and thyroid dysfunction. Monitor for local irritation or allergic contact dermatitis. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical use. Systemic absorption minimal. |
| Fetal Monitoring | No specific monitoring required. Observe for local irritation or allergic reaction. |
| Fertility Effects | No known effects on fertility. Not systemically absorbed significantly. |
| Patient Advice | Do not use if you are allergic to iodine or have a thyroid condition. · For external use only. Avoid contact with eyes, mouth, or open wounds unless directed. · Discontinue and inform your doctor if you develop rash, itching, or swelling. · Store at room temperature away from light. Do not freeze or heat. · Not for use on deep or puncture wounds, or severe burns without medical advice. |